Allogeneic CD19-targeted CAR-γδT Cell therapy(The First Affiliated Hospital of Soochow University)

N/A

Report date: 2024/11/25 20:00:28

Base Information

Drug NameAllogeneic CD19-targeted CAR-γδT Cell therapy(The First Affiliated Hospital of Soochow University)
Drug Alias NameAllogeneic CD19-targeted CAR-γδT Cell Infusion Therapy(The First Affiliated Hospital of Soochow University)QH10304-BAL-01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe First Affiliated Hospital Of Soochow University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Soochow University
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A